⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632193 | 0.82 | — | — | |
| SCHEMBL5526518 | 0.82 | — | — | |
| SCHEMBL18743385 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL104493 | 0.75 | — | — | |
| SCHEMBL12399296 | 0.75 | TSHR (0.41) | — | |
| SCHEMBL727821 | 0.75 | — | — | |
| SCHEMBL24855999 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL7859475 | 0.72 | — | — | |
| SCHEMBL16468814 | 0.71 | — | — | |
| SCHEMBL38322 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001062262-A1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CONCAT, LTD. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| CN-1226888-A | Fluorinated 1,4-disubstituted piperidine derivatives | BANYU PHARMA CO LTD (JP) | 1999-08-25 | — | — | CN | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |